2011～2013年武汉地区34家医院抗血小板药和抗凝血药应用分析

Analysis of Antiplatelet and Anticoagulant Drugs Used in 34 Hospitals in Wuhan Area from 2011 to 2013

目的：了解武汉地区34家医院抗血小板药和抗凝血药临床应用情况,为临床合理用药提供参考。方法：采用回顾性分析方法,对2011-2013年武汉地区34家医院抗血小板药和抗凝血药的销售金额、各药品品种的销售金额、用药频度（DDDs）、药品限定日费用（DDC）和排序比（B/A）进行统计分析。结果：抗血小板药和抗凝血药的销售金额逐年呈上升趋势,氯吡格雷、红花、低分子量肝素销售金额每年均排在前3位;氯吡格雷、华法林、肝素、低分子量肝素、红花DDDs位居前5位,华法林、肝素的DDC小于10元/d;肝素、西洛他唑、舒洛地特、蚓激酶、华法林、吲哚布芬B/A值超过1。结论：武汉地区34家医院抗血小板药和抗凝血药临床应用中,氯吡格雷、华法林、肝素和低分子肝素占主导地位,吲哚布芬、达比加群酯前景可观。

Objective ：To investigate the present situation and tendency of the application of antiplatelet and anticoagulant drugs in 34 hospitals in Wuhan area from 2011 to 2013. Methods：Using the total qualities, consumption sum, defined daily dose （DDD）, frequency of utilization（DDDs）, defined daily cost （DDC） and B/A ratio of antiplatelet and anticoagulant drugs to analyze the situation of clinical use and trend forecast. Results：The total consumption sum increased year by year and the consumption sum of the.top 3 drugs were elopidogrel, Honghua and low molecular weight heparin. The DDDs of the top five drugs were clopidogrel, warfarin, heparin, low molecular weight heparin and Honghua , Moreover, the DDC of warfarin, heparin was less than 10 yuan / day. On the other hand, the B/A values of heparin, cilostazol, Sulodexide, PPA, warfarin and indobufen were all more than 1. Conclusion： In clinical application of antiplatelet and anticoagulant drugs in 34 hospitals in Wuhan area, elopidogrel, warfarin, heparin and low molecular weight heparin were dominated from 2011 to 2013, dabigatran etexilate and indobufen is promising in the future.